GWM
OTLK icon

Gilpin Wealth Management’s Outlook Therapeutics OTLK Stock Holding History

Gilpin Wealth Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$882K Sell
555,000
-45,162
-8% -$28K 0.61% 50
2026
Q1 		$124K Buy
600,162
+245,962
+69% +$106K 0.1% 151
2025
Q4 		$560K Buy
+354,200
New +$566K 0.44% 64

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Gilpin Wealth Management's OTLK Position: Q2 2026 in Review

Gilpin Wealth Management reduced its Outlook Therapeutics (OTLK) stake by 7.5% in Q2 2026, selling an estimated $28K and leaving 555,000 shares worth $882K. The position accounts for 0.61% of the portfolio, ranked #50.

Gilpin Wealth Management first reported a position in OTLK in Q4 2025 and has held it in 3 quarters since. 70 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Gilpin Wealth Management held 555,000 shares of Outlook Therapeutics worth $882K as of Q2 2026.
  • Gilpin Wealth Management sold 45,162 Outlook Therapeutics shares in Q2 2026, an estimated $28K.
  • Outlook Therapeutics made up 0.61% of Gilpin Wealth Management's portfolio in Q2 2026, its #50 holding.
  • Gilpin Wealth Management first reported a position in Outlook Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 70 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Gilpin Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.